OBJECTIVES: Evaluate the safety and efficacy of collagenase in improving flexion deformity, range of motion, and grip strength in patients with residual Dupuytren's disease.

Condition	Treatment or Intervention	Phase
Dupuytren's Contracture	Drug: collagenase	Phase II

PROTOCOL OUTLINE: This is a randomized, investigator-blinded, placebo-controlled study. Patients receive a single dose of either collagenase or placebo into the target finger on day 0. Patients who do not respond at the 1 month follow up visit may receive an injection of open label collagenase, if IgE antibody levels are no greater than 15 ng/mL. Following treatment, patients use a nighttime extension splint for 4 months and perform finger flexion/extension exercises. Patients are followed at 1, 7, and 14 days, and at 1, 2, 3, 6, 9, and 12 months, for each joint treated.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of residual Dupuytren's disease with fixed flexion deformity of the fingers of at least 20-30 degrees caused by a palpable cord Positive table top test (inability to simultaneously place affected finger and palm flat against a table top) --Prior/Concurrent Therapy-- Surgery: At least 30 days since surgery for Dupuytren's disease Other: At least 30 days since prior investigational drug --Patient Characteristics-- Hematopoietic: No history of hematologic disease Hepatic: No history of hepatic disease Renal: No history of renal disease Cardiovascular: No congestive heart failure within 6 months No angina within 6 months No myocardial infarction within 6 months Pulmonary: No history of respiratory disease Other: HIV negative Not immunocompromised No history of significant illness, e.g., endocrine or neurologic disease No history of illicit drug abuse or alcoholism within 1 year No psychosis At least 2 weeks since infectious illness No chronic or debilitating disease No IgE antibodies to collagenase greater than 15 ng/mL No known allergy to collagenase or any of the inactive ingredients in the injection Not pregnant or nursing Fertile patients must use effective contraception

California
      Stanford University Hospital, Palo Alto,  California,  94304,  United States; Recruiting
New York
      State University of New York Health Sciences Center - Stony Brook, Stony Brook,  New York,  11790-7775,  United States; Recruiting

Study chairs or principal investigators

Lawrence C. Hurst,  Study Chair,  State University of New York   

Study ID Numbers:  199/13297; SUNY-SB-FDR001373; DUPY-101; DUPY-202; SUNY-SB-431-1007A; SUNY-SB-431-8804B; SUNY-SB-431-X2020
Record last reviewed:  May 2001
Record first received:  October 18, 1999
ClinicalTrials.gov Identifier:  NCT00004409
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-09